Neisseria meningitidis serogroup b nhba fusion protein antigen

DB10783ApprovedInvestigationalVaccines

Neisseria meningitidis serogroup b nhba fusion protein antigen: Overview.

First approval
Canada, 2015 · United States, 2015 · European Union, 2013
Also known as
Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen
Brand names
  • Bexsero
  • Penmenvy

Resolves to

Compound
UNII28E911Y7AE
Clinical / RWD
RxNorm1601233

What you can answer from here — as of April 02, 2025

46Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
16Marketed productsAcross 5 countries and 5 labellers
Sign in

Which other approved drugs treat the same conditions as Neisseria meningitidis serogroup b nhba fusion protein antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In